{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.1604.1604",
    "article_title": "First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study ",
    "article_date": "December 7, 2017",
    "session_type": "632. Chronic Myeloid Leukemia: Therapy: Poster I",
    "abstract_text": "Background: Dasatinib (DAS) is a 2 nd generation (2 nd gen) tyrosine kinase inhibitor (TKI) approved for 1 st line treatment of chronic myeloid leukemia (CML) patients based on DASISION study results. Most data on 2 nd generation TKIs are from company-sponsored studies, but the patient selection and the high rate of patient switching to other treatments may jeopardize data interpretation. Interestingly, despite significant differences in terms of cytogenetic and molecular response, 2 nd gen TKIs did not produce relevant advantages in terms of overall survival (OS). A post-marketing surveillance in large independent trials is extremely important to confirm efficacy and the safety data. Aims: To describe, in the clinical practice, the response to DAS and the events leading to permanent treatment discontinuation. Methods: An italian multicentric prospective observational study of CML patients treated frontline with DAS has been conducted by the GIMEMA CML Working Party. DAS was given at the discretion of investigators, according to prescribing information, without any exclusion criteria, apart from age (<18 years old) and prior treatment with TKIs or interferon. Molecular response was assessed in standardized molecular laboratories (Labnet network): major molecular response (MR3.0 or MMR), BCR-ABL1 < 0.1% IS; MR4.0, BCR-ABL1 < 0.01% IS or undetectable disease with \u226510,000 ABL1 copies; MR4.5, BCR-ABL1 < 0.0032% IS or undetectable disease with \u226532,000 ABL1 copies. Progression was defined as transformation to advanced (accelerated or blast) phase, according to ELN criteria. Results: 147 CML patients in early chronic phase have been enrolled in 27 italian hematologic centers. The median age was 57 years (65 years or older: 34% of patients). High risk patients according to Sokal, Euro and EUTOS score were 28%, 11%, and 13%, respectively. Median follow-up: 12 months. At 3 months, 88% of patients had BCR-ABL1 transcript levels < 10% IS (at the same timeopoint, < 1% in 66% of patients). At 6 months, 81% of patients had BCR-ABL transcript levels < 1%. The MMR rates at 6 and 12 months were 53% and 72%, respectively. The proportion of patients achieving a MR4 or a MR4.5 at least once was 35% and 16%, respectively. At the last contact, the patients still on treatment with DAS were 88%, while 12% permanently interrupted the study drug. The reasons for study discontinuation were: 1% progression in advanced phase, 2% failure, 1% unrelated death, 1% lost to follow-up, 7% adverse event (1% hematologic toxicity, 4% pleural effusion, 1% tachyarrythmia, 1% other non-hematologic adverse event). No pulmonary hypertension or cardiovascular ischemic adverse events were reported. The probability of OS and progression-free survival at 1 year was 98% and 99%, respectively. Conclusion: The median age of patients receiving DAS in our observational trial was close to the median age reported in population-based CML registries, with one third of patients at least 65 years old; consequently, we may argue that, outside of clinical trials, the decision to treat or not to treat patients with DAS is probably not influenced by age. The proportion of high risk patients, as expected, was higher than reported by population-based CML registries. High molecular response rates were observed and the most frequent reason of permanent treatment discontinuation was the occurrence of adverse events (in particular, pleural effusion). Disclosures Castagnetti: Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Gugliotta: Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Breccia: Novartis: Consultancy; Pfizer: Consultancy; Incyte: Consultancy; Bristol Myers Squibb: Consultancy. Iurlo: Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Stagno: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Abruzzese: Novartis: Consultancy; Incyte: Consultancy; BMS: Consultancy; Pfizer: Consultancy. Crugnola: Celgene: Honoraria; BMS: Honoraria; Novartis: Honoraria. Specchia: Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Tiribelli: Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Bonifacio: Incyte: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees. Galieni: Abbvie: Other: Advisory Board; Takeda: Other: Advisory Board. Soverini: Incyte Biosciences: Consultancy; Novartis: Consultancy; Bristol-Myers Squibb: Consultancy. Fo\u00e0: Roche: Consultancy, Speakers Bureau; janssen: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Sandoz: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Martinelli: ARIAD/INCYTE: Consultancy; ROCHE: Consultancy; JOHNSON & JOHNSON: Consultancy; CELGENE: Consultancy; PFIZER: Consultancy; AMGEN: Consultancy. Saglio: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Ariad: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Pane: Novartis: Honoraria, Speakers Bureau. Baccarani: Novartis: Consultancy, Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Incyte ARIAD: Consultancy, Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau. Rosti: Pfizer: Research Funding, Speakers Bureau; Incyte: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau.",
    "topics": [
        "dasatinib",
        "leukemia, myelocytic, chronic",
        "observational studies",
        "protein-tyrosine kinase inhibitor",
        "adverse event",
        "measles-mumps-rubella vaccine",
        "pleural effusion",
        "withdrawing treatment",
        "bcr-abl tyrosine kinase",
        "follow-up"
    ],
    "author_names": [
        "Fausto Castagnetti, MD PhD",
        "Gabriele Gugliotta, MD PhD",
        "Massimo Breccia, MD PhD",
        "Federica Sor\u00e0, MD",
        "Alessandra Iurlo, MD PhD",
        "Antonella Gozzini, MD",
        "Anna Rita Scortechini, MD",
        "Luigia Luciano, MD",
        "Fabio Stagno, MD PhD",
        "Alessandra Malato, MD",
        "Elisabetta Abruzzese, MD",
        "Monica Crugnola, MD",
        "Patrizia Pregno, MD",
        "Giorgina Specchia, MD",
        "Pellegrino Musto, MD",
        "Nicola Cascavilla, MD",
        "Mario Tiribelli, MD",
        "Massimiliano Bonifacio, MD",
        "Piero Galieni, MD",
        "Fausto Palmieri, MD",
        "Simona Soverini, PhD",
        "Maria Teresa Bochicchio",
        "Simona Sica, MD",
        "Robin Fo\u00e0, MD",
        "Michele Cavo, MD",
        "Giovanni Martinelli, MD",
        "Giuseppe Saglio, MD PhD",
        "Fabrizio Pane, MD",
        "Michele Baccarani, MD",
        "Gianantonio Rosti, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Fausto Castagnetti, MD PhD",
            "author_affiliations": [
                "Institute of Hematology \"L. and A. Ser\u00e0gnoli\", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, \"S. Orsola-Malpighi\" Hospital, Bologna, Italy "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Gabriele Gugliotta, MD PhD",
            "author_affiliations": [
                "Department of Experimental Diagnostic and Specialty Medicine - DIMES Institute of Hematology \"L. e A. Ser\u00e0gnoli\", University of Bologna, Bologna, Italy "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimo Breccia, MD PhD",
            "author_affiliations": [
                "Dipartimento Biotecnologie Cellulari, University of Rome \"Sapienza\", Roma, Italy "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Federica Sor\u00e0, MD",
            "author_affiliations": [
                "Hematology Unit, Policlinico \"A. Gemelli\", Universit\u00e0 Cattolica del Sacro Cuore, Roma, Italy "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandra Iurlo, MD PhD",
            "author_affiliations": [
                "Hematology Division, IRCCS C\u00e0 Granda - Maggiore Policlinico Hospital Foundation, Milano, Italy "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonella Gozzini, MD",
            "author_affiliations": [
                "SC Terapie Cellulari e Medicina Trasfusionale, AOU Careggi, Florence, Italy "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Rita Scortechini, MD",
            "author_affiliations": [
                "Hematology Unit, A.O.U. Ospedali Riuniti, Ancona, Italy "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luigia Luciano, MD",
            "author_affiliations": [
                "Hematology - Department of Clinical Medicine and Surgery, Federico II University, Napoli, Italy "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabio Stagno, MD PhD",
            "author_affiliations": [
                "Hematology Section, Biomedical Sciences, University of Catania, Trecastagni, ITA "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandra Malato, MD",
            "author_affiliations": [
                "UOC di Ematologia con UTMO, Ospedali Riuniti Villa Sofia-Cervello, Palermo, ITA "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elisabetta Abruzzese, MD",
            "author_affiliations": [
                "Hematology Unit, S.Eugenio Hospital, Tor Vergata University, Rome, ITA "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Monica Crugnola, MD",
            "author_affiliations": [
                "Division of Hematology, University Hospital of Parma, Parma, Italy "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Patrizia Pregno, MD",
            "author_affiliations": [
                "Az Osp Citta' Della Salute E Scienza Torino, University of Torino, TORINO, Italy "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giorgina Specchia, MD",
            "author_affiliations": [
                "University of Bari, Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, Bari, Italy "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pellegrino Musto, MD",
            "author_affiliations": [
                "IRCCS CROB, Referral Cancer Center of Basilicata, Rionero In Vulture, ITA "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicola Cascavilla, MD",
            "author_affiliations": [
                "Casa Sollievo Della Sofferenza IRCCS, San Giovanni Rotondo, Italy "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Tiribelli, MD",
            "author_affiliations": [
                "Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimiliano Bonifacio, MD",
            "author_affiliations": [
                "Department of Medicine, Section of Haematology, University of Verona, Verona, Italy "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Piero Galieni, MD",
            "author_affiliations": [
                "U.O.C. Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fausto Palmieri, MD",
            "author_affiliations": [
                "Hematology Unit, Ospedale \"S. G. Moscati\", Avellino, Italy "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Simona Soverini, PhD",
            "author_affiliations": [
                "Institute of Hematology \"L. e A. Ser\u00e0gnoli\", University of Bologna, Castel Maggiore, Italy "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Teresa Bochicchio",
            "author_affiliations": [
                "Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \"L. and A. Ser\u00e0gnoli\", University of Bologna, \"S. Orsola-Malpighi\" Hospital, Bologna, Italy "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Simona Sica, MD",
            "author_affiliations": [
                "Hematology Unit, Fondazione Policlinico Universitario A Gemelli Universit\u00e0 Cattolica, Roma, Italy "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robin Fo\u00e0, MD",
            "author_affiliations": [
                "Hematology Unit, Sapienza University of Rome, Rome, Italy "
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Cavo, MD",
            "author_affiliations": [
                "Department of Physics and Astronomy, University of Bologna, Bologna, Italy "
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giovanni Martinelli, MD",
            "author_affiliations": [
                "Institute of Hematology 'Seragnoli', Institute of Hematology 'Seragnoli', Bologna, Italy "
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Saglio, MD PhD",
            "author_affiliations": [
                "University of Turin, Orbassano, Italy "
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabrizio Pane, MD",
            "author_affiliations": [
                "Hematology - Departments of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy "
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Baccarani, MD",
            "author_affiliations": [
                "Institute of Hematology \"L. e A. Ser\u00e0gnoli\", University of Bologna, Bologna, Italy "
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gianantonio Rosti, MD",
            "author_affiliations": [
                "Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Institute of Hematology \"L. and A. Ser\u00e0gnoli\", S.Orsola-Malpighi University Hospital, Bologna, Italy"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-10T15:37:48",
    "is_scraped": "1"
}